Peter Max
- CEO Partner
Transaction Description
Gemstone acted as financial advisor in Prostatype’s Unit Rights Issue. The Rights Issue was subscribed to a total of approximately 66.0 percent, including pre-subscription commitments, resulting in guarantee commitments of a total of approximately 6.1 percent being activated to achieve a subscription rate of 72.1 percent. In addition, a total of SEK 3.8 million worth of debt has been converted in the Rights Issue resulting in a total subscription of 79.8 percent.
Contact Person
Company Description
Prostate cancer is one of the most common forms of cancer and approximately 1.3 million men are diagnosed annually. Prostatype Genomics has developed an algorithm-based kit specifically designed to eliminate the misclassification of prostate cancer, which can lead to inappropriate treatment and dosages. Such misclassification often results in unnecessary side effects and requires multiple treatment courses. This innovative kit seamlessly integrates with current diagnostic procedures and tests, ensuring no disruption to the existing healthcare process.
Financial and strategic advisors
to high caliber growth companies
in pursuit of market leadership.
© 2025 Gemstone Capital – Designet af Aveo webmarketing